Related Experiment Video

Updated: Jun 28, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Regression of glomerular injury by losartan in experimental diabetic nephropathy

Flávio Teles1, Flávia G Machado, Bianca H Ventura

  • 1Laboratory of Renal Pathophysiology (LIM-16), Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.

Kidney International
|October 24, 2008
PubMed

Insights

Losartan treatment can reduce mesangial expansion and sclerotic lesions in diabetic kidney disease. However, advanced glomerular lesions like synechiae may not fully resolve, even with high-dose treatment.

Area of Science:

  • Nephrology
  • Diabetology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) features can be reversible.
  • The potential for regression of advanced glomerular lesions, such as synechiae, during treatment remains unclear.
  • Previous studies indicated a dose-dependent renoprotective effect of AT-1 receptor blockers like losartan.

Purpose of the Study:

  • To investigate the regression of moderate and advanced glomerular lesions in streptozotocin-induced diabetes.
  • To evaluate the efficacy of conventional and high-dose losartan treatment on these lesions.
  • To determine if losartan exhibits a dose-response effect in this diabetic nephropathy model.

Main Methods:

  • Diabetic adult male Munich-Wistar rats were induced using streptozotocin and maintained with daily insulin for 10 months.
  • Following the induction period, rats received insulin with or without conventional or high-dose losartan for 2 additional months.
  • Histopathological analysis was performed to assess mesangial expansion and synechiae lesions.

Main Results:

  • Diabetic rats exhibited mesangial expansion, which worsened with continued insulin treatment alone.
  • Both conventional and high-dose losartan treatments significantly reduced mesangial expansion and the severity of synechiae lesions compared to baseline.
  • The frequency of synechiae lesions did not change, and no dose-response effect of losartan was observed.

Conclusions:

  • Regression of mesangial expansion and contraction of sclerotic lesions are achievable in diabetic kidney disease treatment.
  • Complete resolution of advanced glomerulosclerosis, including synechiae, may be challenging.
  • Losartan treatment shows potential in mitigating diabetic nephropathy complications, but full reversal of advanced lesions is not guaranteed.

More Related Videos

Assessment of Kidney Function in Mouse Models of Glomerular Disease09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...